Header Logo

Connection

Yehuda Handelsman to Hyperlipidemias

This is a "connection" page, showing publications Yehuda Handelsman has written about Hyperlipidemias.
Connection Strength

0.729
  1. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.
    View in: PubMed
    Score: 0.543
  2. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgrad Med. 2012 Jul; 124(4):14-20.
    View in: PubMed
    Score: 0.097
  3. Treatment of the insulin resistance syndrome. Endocr Pract. 2003 Sep-Oct; 9 Suppl 2:99-104.
    View in: PubMed
    Score: 0.053
  4. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.